Colorado Representative Tim Geitner [R]

Filter View [Reset All]
Syndicate content
StanceStateBillStatusSummary/TitleLast Actionsort icon
COHB1027Engross
50%
Concerning the extension of the small retailer exception to the sales and use tax destination sourcing rules.
[Detail][Text][Discuss]
2022-01-26
Senate Committee on Business, Labor, & Technology Refer Unamended - Consent Calendar to Senate Committee of the Whole
COHB1123Intro
25%
Concerning an inflationary adjustment to the federal standard deduction for purposes of providing state income tax relief.
[Detail][Text][Discuss]
2022-01-21
To House Finance Committee
COHJR1003PassConcerning the commemoration of the birthday of the Reverend Dr. Martin Luther King, Jr.
[Detail][Text][Discuss]
2022-01-20
Signed by the President of the Senate
COHR1001PassConcerning employees and positions for the House of Representatives convened in the Second Regular Session of the Seventy-third General Assembly.
[Detail][Text][Discuss]
2022-01-19
Signed by the Speaker of the House
COHB1084Intro
25%
Concerning cancellation of the voter registration of certain ineligible jurors, and, in connection therewith, requiring the state court administrator to provide the secretary of state with a report of all persons who report as ineligible to serve as ...
[Detail][Text][Discuss]
2022-01-19
To House State, Civic, Military and Veterans Affairs Committee
COSJR001PassConcerning the Officers and Employees of the Second Regular Session of the Seventy-third General Assembly.
[Detail][Text][Discuss]
2022-01-18
Signed by the Speaker of the House
COHB1066Intro
25%
Concerning requiring public education entities to improve academic transparency by providing easily accessible information to the public, and, in connection therewith, making an appropriation.
[Detail][Text][Discuss]
2022-01-14
To House Education Committee
COSB041Intro
25%
Concerning increasing pretrial release requirements for certain criminal defendants.
[Detail][Text][Discuss]
2022-01-14
To Senate Judiciary Committee
COHB1015Intro
25%
Concerning the ability of certain health-care providers to repurpose therapeutic drugs that have been approved by the federal food and drug administration for another purpose to provide treatment to individuals with COVID-19.
[Detail][Text][Discuss]
2022-01-12
To House Health & Insurance Committee
Syndicate content
feedback